The Electrophysiology Research Foundation<\/u><\/span><\/strong> is a charitable organization incorporated on August 2, 1982. The Foundation is a non-profit corporation, organized and operated exclusively for charitable purposes.<\/span><\/p>\n<\/div> Contributions to Science<\/strong><\/p>\n Scientific work that contributed to current therapy of arrhythmias <\/strong><\/p>\n \u27a2 1981- Firs and pivotal description of the anatomic location of the slow AV nodal pathway which established the basis for slow pathway mapping and ablation ( Circulation 1981) <\/em><\/p>\n \u27a2 1981 \u2013 First implantation of antitachycardia pacemakers for ventricular tachycardia, later extended to supraventricular tachycardia <\/em><\/p>\n \u27a2 1983: Principal Investigator in first clinical FDA trials of the implantable defibrillator ( AID, Mirowski)<\/p>\n \u27a2 1983- First pivotal study of DC shock AV junctional ablation (Scheinman) and later for ablation of AV nodal reentry, accessory pathways in the right atrium , coronary sinus and left sided endocardial ablation <\/em><\/p>\n \u27a2 1983: Intraoperative spectral analysis of ventricular electrograms during sinus rhythm and ventricular tachycardia. PACE 1983 <\/em><\/p>\n \u27a2 1983- Mechanisms of left ventricular dysfunction during ventricular pacing and ventricular tachycardia in man. (PACE 1983) <\/em><\/p>\n \u27a2 1983-85: Direct hemodynamic during spontaneous and induced ventricular tachycardia in man which were the first human studies ( JACC 1984) <\/em><\/p>\n \u27a2 1984- Pivotal study on antitachycardia pacing that established it as first line electrical therapy in ventricular tachycardia in preference to shock therapy <\/em>( Circulation 1985;1:571- 578))<\/p>\n \u27a2 1984- Echocardiographic studies of ventricular and mitral valve function during spontaneous and induced ventricular tachycardia in man which were the first human studies (PACE 1984) <\/em><\/p>\n \u27a2 1983-85 \u2013 Demonstrated experimental and clinical feasibility of laser ablation of VT, later SVT in the<\/p>\n intraoperative studies and published first clinical results ( Am. J. Cardiology 1986) <\/em><\/p>\n \u27a2 1984- RF ablation experimental studies published from experimental lab and development of active fixation and suction electrode catheters for both DC and RF ablation . <\/em><\/p>\n \u27a2 1985- Reported the first 3 lead non-thoracotomy lead system for cardioversion and defibrillation and was issued a patent by the US government for the first non-thoracotomy lead system for human defibrillation <\/em><\/p>\n \u27a2 1987 \u2013 Performed first successful implantation of an ICD without thoracotomy (JAMA 1988)<\/p>\n \u27a2 1987- First radiofrequency AV junctional ablation with first RF ablation generator in NJ and ( Osypka RF device, Am J Cardiol 1989) <\/em><\/p>\n \u27a2 1985-88- Subcutaneous electrode mapping studies that now are used in subcutaneous defibrillators and extravascular ICD lead placement <\/em><\/p>\n \u27a2 1987- Development of the first sequential pacing and cardioversion algorithm for use in ICDs and now is standard in all devices (Circulation 1987;76:601-609) <\/em><\/p>\n \u27a2 1987-1994: Developed and tested new endocardial defibrillation lead systems for ICDs including the Medtronic, Endotak series leads , braided electrode system for Telectronics <\/em><\/p>\n \u27a2 1989- First report of defibrillation lead fracture and failures ( Arch, Int.Mmed 1989) <\/em><\/p>\n \u27a2 1991: First studies on biphasic shock defibrillation with threshold reduction in humans which is now the standard for ICDs (PACE 1991) <\/em><\/p>\n \u27a2 1987 \u2013 Established first scientific standards for antitachycardia pacemakers and ICDs: NASPE Board of Trustees and co-chaired first policy conference and position statement on implantable antitachycardia devices ( with J. Camm) in 1987 and the indications for the ICD ( with M. Lehmann) 1990 <\/em><\/p>\n \u27a2 1988: Implantation of the first pacemaker defibrillator<\/p>\n \u27a2 1994-95- First coronary sinus ablation of left sided accessory pathways with RF <\/em>PACE 1995, AJC 1995)<\/p>\n \u27a2 Proposed the terms ICD (implantable cardioverter-defibrillator) in 1987 and Interventional Electrophysiology in 1990 <\/em><\/p>\n \u27a2 1991: Began his collaboration with the NHLBI resulting in the development of the AVID trial (1992) and AFFIRM trial (1996); Joint policy conferences with the ACC,AHA, ESC and FDA <\/em><\/p>\n \u27a2 1994-Developed Dual Site Atrial Pacing and clinical results (JACC 1996), RCT ( JACC 2002)<\/p>\n \u27a2 1998-2010: Bi-atrial Mapping &Origin of Atrial Fibrillation first proposed , not widely accepted with mainstream PVI hypothesis but continued to championed by us, and now extra PV sources are widely accepted (AJC 1998-JCE 2005) <\/em><\/p>\n \u27a2 1999: First report on the AVID trial on ejection fraction as a stratifier for ICD benefit on whose basis the entire series of MADIT 2 and SCD-HeFT trials were based <\/em><\/p>\n \u27a2 1999: Co-chaired first Round Table with the NIH\/NASPE on future research directions in EP which led to NIH placing atrial fibrillation and sudden death in their top 5 public health priorities for NHLBI in 2002 <\/em><\/p>\n \u27a2 Directed the development of new intracardiac echo technology (ViewMate,EP Med Systems) which now still is in use. <\/em><\/p>\n \u27a2 2010 \u2013Principal investigator for the First RCT of intracardiac echo (ICE CHIP) which was reported in Circulation EP <\/em><\/p>\n \u27a2 2004- Joined NIH HFpEF planning group and TOPCAT study group and Steering Committee of the TOPCAT RCT ( NEJM 2014) <\/em><\/p>\n \u27a2 Established research interest in the AF-HFpEF syndrome ( JICE 2018) <\/em><\/p>\n \u27a2 2020- Pivotal AFFIRM substudy showing the benefits of rhythm control in preventing HF emergence in AF ( AHJ 2020); <\/em><\/p>\n \u27a2 2020- Developed and initiated the first trial to compare rhythm control options( ablation vs. AAD) in AF with HFpEF: Study Chair TAP-CHF trial ( 2022-2024) <\/em><\/p>\n \u27a2 1982 \u2013 2024 Principal investigator in in over 69 clinical trials<\/p>\n \u27a2 Published over 375 original research papers with the majority as first author, over 475 research presentations, faculty and lecturer > 500 national and international meetings <\/strong><\/p>\n \u27a2 Many of his early studies and later studies are only now being mined as the basis for new directions in understanding pathophysiology, hemodynamics and new therapeutic directions in tachycardia therapy. <\/strong><\/p>\n \u27a2 Edited 9 textbooks of Cardiology and Electrophysiology<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-350","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages\/350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/comments?post=350"}],"version-history":[{"count":5,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages\/350\/revisions"}],"predecessor-version":[{"id":418,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages\/350\/revisions\/418"}],"wp:attachment":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/media?parent=350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"http:\/\/eprf.net\/wp-content\/uploads\/2020\/01\/header-telephone.png\")
\u00a0 \u00a0 1-732-302-9990<\/a>
\n<\/span>![\"\"](\"http:\/\/eprf.net\/wp-content\/uploads\/2020\/01\/header-mail.png\")
\u00a0 \u00a0 info@eprf.net<\/a><\/span><\/span><\/p>\n<\/div>Advances In Research<\/b><\/font><\/h2>\n<\/div>